| Gene symbol and protein | Gene Location | All allelic disease phenotypes - locus/disease symbols |
| 1 | AARS2 Alanyl-tRNA synthetase 2, mitochondrial(M) | 6p21.1 |  | Mitochondrial hypertrophic cardiomyopathy related to AARS2 - COXPD8 (10.33)
|
|
| 2 | ACAD9 Acyl-CoA dehydrogenase family member 9(M) | 3q21.3 | | Mitochondrial complex 1 deficiency, nuclear type 20 - MC1DN20 (9.26)
|
|
| 3 | ACADVL Acyl-Coenzyme A dehydrogenase, very long chain(M) | 17p13 | | Acyl-CoA dehydrogenase (very long chain) deficiency - VLCAD (9.25)
|
|
| 4 | AFG3L2 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) 1(M) | 18p11-q11 | | Spinocerebellar ataxia 28 - SCA28 (13.25, 15.80)
| | Spastic ataxia 5 autosomal recessive - SPAX5 (13.25, 15.80)
|
|
| 5 | AIFM1 Apoptosis-inducing factor, Mitochondria-associated 1(M) | Xq24-q26.1 | | Neuropathy, axonal motor-sensory, with deafness and mental retardation - NAMSD (13.102, 14.40, 16.64)
| | Charcot-Marie-Tooth disease, X-linked 4 (Cowchock syndrome) - COWCK (13.102, 14.40, 16.64)
| | Charcot-Marie-Tooth disease with deafness and mental retardation - NAMSD (13.102, 14.40, 16.64)
| | Combined Oxidative phosphorylation Deficiency 6 - COXPD6 (13.102, 14.40, 16.64)
| | Cerebellar ataxia with neuropathy, hearing loss and intellectual disability - (13.102, 14.40, 16.64)
|
|
| 6 | ALDH18A1 Aldehyde deydrogenase 18 family, member A1 (M) | 10q24.1 | | Spastic paraplegia 9 - SPG9A (15.5, 15.25)
| | Spastic paraplegia 9A, autosomal recessive - SPG9B (15.5, 15.25)
|
|
| 7 | APOO Apolipoprotein O(M) | Xp22.11 | | Mitochondrial myopathy with lactic acidosis, cognitive impairment and autistic features - (16.82)
|
|
| 8 | ATP13A2 ATPase, type 13A2(M) | 1q36.13 | | Spastic paraplegia 78, autosomal recessive - SPG78 (15.66)
|
|
| 9 | C12orf65 Chomosome 12 open reading frame 65(M) | 12q24.31 | | Spastic paraplegia 55, autosomal recessive - SPG55 (15.54)
|
|
| 10 | C19orf12 Chromosome 19 open reading frame 12(M) | 19q12 | | Spastic paraplegia 43, autosomal recessive - SPG43 (15.42)
| | Neurodegeneration with brain iron accumulation 4 - NBIA4 (15.42)
|
|
| 11 | CASQ1 Calsequestrin 1 (fast-twitch, skeletal muscle)(M) | 1q21 | | Vacuolar myopathy with CASQ1 aggregates - VMCQA (5.40)
|
|
| 12 | CAVIN1 Caveolae-associated protein 1(M) | 17q21-q2 | | lipodystrophy, congenital generalized, type 4 - CGL4 (1.13)
|
|
| 13 | CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10(M) | 22q11.2-q13.2 | | Amyotrophic lateral sclerosis and/or frontotemporal dementia - FTDALS2 (12.38, 12.76, 16.62)
| | late-onset spinal motor neuronopathy, Jokela type - SMAJ (12.38, 12.76, 16.62)
|
|
| 14 | COQ2 Coenzyme Q2(M) | 4q21.23 | | Coenzyme Q10 deficiency 1 - COQ10D1 (16.73)
|
|
| 15 | COQ4 Coenzyme Q4(M) | 9q34.11 | | Coenzyme Q10 deficiency 7 - COQ10D7 (16.77)
|
|
| 16 | COQ5 Coenzyme Q5 Methyltransferase(M) | 12q24.31 | | Coenzyme Q10 deficiency - COQ10D9 (13.104)
|
|
| 17 | COQ6 Coenzyme Q6(M) | 14q24.3 | | Coenzyme Q10 deficiency 6 - COQ10D6 (16.76)
|
|
| 18 | COQ7 Coenzyme Q7(M) | 16p12.3 | | Coenzyme Q10 deficiency 8 - COQ10D8 (16.78)
|
|
| 19 | COQ9 Coenzyme Q9(M) | 16q21 | | Coenzyme Q10 deficiency 5 - COQ10D5 (16.75)
|
|
| 20 | COX15 COX15 homolog, cytochrome c oxidase assembly protein (yeast)(M) | 10q24 | | Mitochondrial complex IV deficiency, nuclear type 6 - MC4DN6 (CEMCOX2) (10.38)
|
|
| 21 | COX6A1 Cytochrome c oxidase subunit VIa polypeptide 1(M) | 12q24.31 | | CMT recessive intermediate D - CMTRID (14.87)
|
|
| 22 | COX6A2 Cytochrome c-oxidase, subunit 6A2(M) | 16p11.2 | | Mitochondrial complex IV deficiency, nuclear type 18 - MC4DN18 (16.69)
|
|
| 23 | CPT1C Carnitine Palmitoyltransferase 1C(M) | 19q13.33 | | Spastic paraplegia 73, autosomal dominant - SPG73 (15.20)
|
|
| 24 | CPT2 Carnitine palmitoyltransferase II(M) | 1p32 | | CPT deficiency, hepatic, type II - CPT2 (9.19)
| | Hypoglycemia hypoketonic related to carnitine palmitoyltransferase II - CPTase (9.19)
| | Myopathy due to CPT II deficiency - CPT2 (9.19)
|
|
| 25 | DGUOK Deoxyguanosine kinase(M) | 2p13.1 | | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 4 - PEOB4 (16.42, 16.46)
| | Mitochondrial DNA depletion syndrome 3 (hepatocerebral type) - MTDPS3 (16.42, 16.46)
|
|
| 26 | DHTKD1 Dehydrogenase E1 and transketolase domain containing 1(M) | 10p14 | | Charcot-Marie-Tooth neuropathy Type 2Q - CMT2Q (14.62)
|
|
| 27 | DNA2 DNA replication helicase 2(M) | 10q21.3 | | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6 - PEOA6 (16.38)
|
|
| 28 | ETFA Electron-transfer-flavoprotein, alpha polypeptide(M) | 15q23-q25 | | Multiple acyl-CoA dehydrogenase deficiency (MADD; Glutaric aciduria type IIA) - GAIIA (9.22)
|
|
| 29 | ETFB Electron-transfer-flavoprotein, beta polypeptide(M) | 19q13.3-q13.4 | | Multiple acyl-CoA dehydrogenase deficiency (MADD; Glutaric aciduria type IIB) - GAIIB (9.23)
|
|
| 30 | ETFDH Electron-transferring-flavoprotein dehydrogenase(M) | 4q32-q35 | | Multiple acyl-CoA dehydrogenase deficiency (MADD; Glutaric aciduria type IIC) - GAIIC (9.24)
| | Multiple acyl-coa dehydrogenase deficiency - MADD (9.24)
|
|
| 31 | FARS2 Phenylalanine-tRNA synthetase 2(M) | 6p25.1 | | Spastic paraplegia 77, autosomal recessive - SPG77 (15.65)
|
|
| 32 | FDX2 Ferredoxin(M) | 19p13.2 | | Mitochondrial myopathy, episodic with or withour atrophy and reversible leukoencephalopathy - MEOAL (16.79)
|
|
| 33 | FLAD1 flavin adenine dinucleotide synthetase, homolog(M) | 1q21.3 | | Lipid storage myopathy due to Flavin Adenine Dinucleotide Synthetase Deficiency - LSMFLAD (9.31)
|
|
| 34 | FXN Frataxin(M) | 9q13-q21.1 | | Friedreich ataxia - FRDA (13.54)
| | Friedreich ataxia with retained reflexes - FARR (13.54)
|
|
| 35 | HK1 Hexokinase 1(M) | 10q22.1 | | Charcot-Marie-Tooth neuropathy Type 4G - CMT4G (14.31)
|
|
| 36 | HSPD1 Heat shock 60kDa protein 1 (chaperonin)(M) | 2q33.1 | | Spastic paraplegia 13 - SPG13 (15.8)
|
|
| 37 | IBA57 IBA57 homolog, iron-sulfur cluster assembly (M) | 1q42.13 | | Spastic paraplegia 74, autosomal recessive - SPG74 (15.62)
|
|
| 38 | ISCU Iron-sulfur cluster scaffold homolog (E. coli)(M) | 12q24.1 | | myopathy with exercise intolerance, swedish type - (5.36)
| | myopathy with deficiency of succinate dehydrogenase and aconitase - (5.36)
| | myopathy with lactic acidosis, hereditary - HML (5.36)
|
|
| 39 | KIF1B Kinesin family member 1B(M) | 1p36.2 | | Charcot-Marie-Tooth disease, type 2A1 - CMT2A1 (14.47)
|
|
| 40 | MARS2 Methionyl-tRNA synthetase 2, mitochondrial(M) | 2q33-34 | | autosomal recessive spastic ataxia with leukoencephalopathy - ARSAL (15.78)
|
|
| 41 | MFN2 Mitofusin 2(M) | 1p36.22 | | Hereditary motor and sensory neuropathy 2A - CMT2A2A (14.48, 14.72, 14.78)
| | Charcot-Marie-Tooth disease, axonal, type 2A2B - CMT2A2B (14.48, 14.72, 14.78)
| | Hereditary motor and sensory neuropathy, type VIA with optic atrophy - HMSN6A (14.48, 14.72, 14.78)
|
|
| 42 | MGME1 Mitochondrial genome maintenance exonuclease 1(M) | 20p11.23 | | Mitochondrial DNA depletion syndrome 11 - MTDPS11 (16.53)
|
|
| 43 | MPV17 MpV17 mitochondrial inner membrane protein(M) | 2p23.3 | | Charcot-Marie-Tooth disease, axonal, type 2EE - CMT2EE (14.81)
|
|
| 44 | MRPL3 Mitochondrial ribosomal protein L3(M) | 3q21-q23 | | Hypertrophic mitochondrial cardiomyopathy related to MRPL3 - (10.34)
|
|
| 45 | MRPL44 Mitochondrial ribosomal protein L44(M) | 2q36.1 | | Mitochondrial hypertrophic cardiomyopathy related to MRPL44 - COXPD16 (10.36)
|
|
| 46 | MRPS25 Mitochondrial ribosomal protein S25(M) | 3p25.1 | | Combined oxidative phosphorylation deficiency 50 - COXPD50 (16.68)
|
|
| 47 | MSTO1 Misato homolog 1 (Drosophila)(M) | 1q22 | | Myopathy, mitochondrial and cerebellar ataxia - MMYAT (2.52, 13.100, 16.72)
|
|
| 48 | MTO1 Mitochondrial tRNA translation optimization 1(M) | 6q13 | | Mitochondrial hypertrophic cardiomyopathy related to MTO1 - COXPD10 (10.35)
|
|
| 49 | MTPAP Mitochondrial poly(A) polymerase(M) | 10p12.1 | | Spastic ataxia 4 autosomal recessive - SPAX4 (15.79)
|
|
| 50 | NDUFAF1 NADH-ubiquinone oxidoreductase 1 alpha subcomplex(M) | 15q15.1 | | patient with HCM and isolated respiratory complex I deficiency - (10.31)
| | Hypertrophic mitochondrial cardiomyopathy related to NDUFAF1 - (10.31)
| | Mitochondrial complex 1 deficiency, nuclear type 11 - MC1DN11 (10.31)
|
|
| 51 | OPA1 optic atrophy 1(M) | 3q28-q29 | | Mitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type) - MTDPS14 (16.57, 16.59)
| | Progressive external ophthalmoplegia with optic atrophy, optic atrophy 1 with deafness - (16.57, 16.59)
|
|
| 52 | PDK3 Pyruvate dehydrogenase kinase, isoenzyme 3(M) | Xp22.11 | | Charcot-Marie-Tooth neuropathy X-linked 6 - (14.42)
|
|
| 53 | PNPLA8 Patatin-like phospholipase domain containing 8(M) | 7q31.1 | | Infantile neuroaxonal dystrophy and neutral lipid storage disease with myopathy - MMLA (9.30)
|
|
| 54 | POLG Polymerase (DNA directed), gamma(M) | 15q25 | | Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis - SANDO (13.92, 16.33, 16.39, 16.47, 16.48)
| | spinocerebellar ataxia with epilepsy, included - SCAE (13.92, 16.33, 16.39, 16.47, 16.48)
| | Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal - PEOA1 (13.92, 16.33, 16.39, 16.47, 16.48)
| | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 1 - PEOB1 (13.92, 16.33, 16.39, 16.47, 16.48)
| | Mitochondrial DNA depletion syndrome 4B (MNGIE type) - MTDPS4B (13.92, 16.33, 16.39, 16.47, 16.48)
| | Mitochondrial DNA depletion syndrome 4A (Alpers type) - MTDPS4A (13.92, 16.33, 16.39, 16.47, 16.48)
|
|
| 55 | POLG2 Mitochondrial DNA polymerase, accessory subunit(M) | 17q24.1 | | progressive external ophthalmoplegia, autosomal dominant, 4 - PEOA4 (16.36)
|
|
| 56 | PTRH2 Peptidyl-tRNA Hydrolase 2(M) | 17q23.1 | | Infantile-onset multisystem disease with progressive muscle weakness - IMNEPD (16.71)
|
|
| 57 | PUS1 Pseudouridylate synthase 1(M) | 12q24.33 | | Mitochondrial myopathy and sideroblastic anemia 1 - MLASA1 (16.60)
|
|
| 58 | REEP1 Receptor accessory protein 1(M) | 2p11.2 | | Distal spinal muscular atrophy, type VB - DSMAVB (12.24, 15.12)
| | Spastic paraplegia 31 - SPG31 (12.24, 15.12)
| | Neuronopathy, distal hereditary motor, type VB - HMN5B (12.24, 15.12)
|
|
| 59 | RNASEH1 Ribonuclease H1(M) | 2p25.3 | | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 2 - PEOB2 (16.40)
|
|
| 60 | RRM2B Ribonucleotide reductase M2 B (TP53 inducible)(M) | 8q23.1 | | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal - PEOA5 (16.37, 16.50, 16.51)
| | Mitochondrial DNA depletion syndrome 8A (Encephalomyopathic type with renal tubulopathy) - MTDP8A (16.37, 16.50, 16.51)
|
|
| 61 | SCO2 Cytochrome c oxidase assembly protein(M) | 22q13.33 | | Mitochondrial complex IV deficiency, nuclear type 2 - MC4DN2 (CEMCOX1) (10.37, 14.94)
| | Charcot-Marie-Tooth disease, axonal, related to SCO2 - (10.37, 14.94)
|
|
| 62 | SDHA Succinate dehydrogenase complex, subunit A, flavoprotein (Fp)(M) | 5p15 | | Recessive neonatal isolated DC - (10.70)
| | Cardiomyopathy, dilated, 1GG - CMD1GG (10.70)
|
|
| 63 | SLC25A1 Solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1(M) | 22q11.21 | | Presynaptic congenital myasthenic syndrome 23 - CMS23 (11.31)
|
|
| 64 | SLC25A20 Carnitine-acylcarnitine translocase(M) | 3p21.31 | | Carnitine-acylcarnitine translocase deficiency - CACT (9.21)
|
|
| 65 | SLC25A4 Mitochondrial carrier; adenine nucleotide translocator(M) | 4q35 | | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal - PEOA2 (16.34, 16.54, 16.55)
| | Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) - MTDPS12A (16.34, 16.54, 16.55)
| | Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) - MTDPS12B (16.34, 16.54, 16.55)
|
|
| 66 | SLC25A42 Solute carrier family 25 member 42(M) | 19p13.11 | | Metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression - MECREN (16.58)
| | Mitochondrial myopathy - (16.58)
|
|
| 67 | SLC25A46 solute carrier family 25 member 46(M) | 5q22.1 | | Neuropathy, hereditary motor and sensory, type VIB - HSMN6B (12.95)
|
|
| 68 | SPG7 Paraplegin(M) | 16q24.3 | | Spastic paraplegia 7 - SPG7 (15.24)
|
|
| 69 | SUCLA2 Succinate-CoA ligase, ADP-forming, beta subunit(M) | 13q12.2-q13.3 | | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria) - MTDPS5 (16.49)
|
|
| 70 | SUCLG1 Succinate-CoA ligase, alpha subunit(M) | 2p11.2 | | Mitochondrial DNA depletion syndrome 9 (Encephalomyopathic type withmethylmalonic aciduria) - MTDPS9 (16.52)
|
|
| 71 | SURF1 Surfeit 1(M) | 9q34.2 | | Charcot-Marie-Tooth neuropathy Type 4K - CMT4K (14.34)
|
|
| 72 | TIMM22 Translocase of inner mitochondrial membrane 22(M) | 17q13.3 | | Combined oxidative phosphorylation deficiency 43 - COXPD43 (16.65)
|
|
| 73 | TK2 Thymidine kinase 2, mitochondrial(M) | 16q22-q23 | | Mitochondrial dna depletion syndrome, myopathic form - MTDPS3 (13.28, 16.41, 16.45)
| | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 3 - PEOB3 (13.28, 16.41, 16.45)
|
|
| 74 | TMEM126B Transmembrane protein 126B(M) | 11q14.1 | | Mitochondrial complex I deficiency, nuclear type 29 - MC1DN29 (16.81)
|
|
| 75 | TSFM Ts translation elongation factor, mitochondrial(M) | 12q14.1 | | Mitochondrial hypertrophic cardiomyopathy related to TSFM - COXPD3 (10.32)
|
|
| 76 | VAMP1 Vesicle associated membrane protein (synaptobrevin 1)(M) | 12p13 | | ataxia, spastic, 1, autosomal dominant - SPAX1 (11.33, 15.76)
| | Presynaptic congenital myasthenic syndrome 25 - CMS25 (11.33, 15.76)
|
|
| 77 | WWOX WW Domain-Containing Oxidoreductase(M) | 16q23.1-q23.2 | | Spinocerebellar ataxia, autosomal recessive 12 - SCAR12 (13.68)
|
|
| 78 | YARS2 Tyrosyl-tRNA synthetase 2, mitochondrial(M) | 12p11.21 | | Myopathy, lactic acidosis, and sideroblastic anemia-2 - MLASA2 (16.61)
|
|
